Genomic organization and expression of the human beta-synuclein gene (SNCB).

Abstract

The beta-synuclein protein is highly homologous to the alpha-synuclein protein for which two mutations were reported in some familial cases of Parkinson disease. It has been shown that both alpha- and beta-synucleins may be able to inhibit phospholipase D2 selectively. We have observed that the beta-synuclein gene (HGMW-approved symbol, SNCB) is highly expressed in brain including the substantia nigra, the main region of neuronal degeneration in patients with Parkinson disease. We have determined the intron-exon structure of the beta-synuclein gene and established sequencing assays that will facilitate the search for mutations in the beta-synuclein gene in patients with Parkinson disease or other neurodegenerative disorders.

• Authors: C Lavedan, E Leroy, R Torres, A Dehejia, A Dutra, S Buchholtz, R L Nussbaum, M H Polymeropoulos
• Journal: Genomics (Genomics) Vol. 54 Issue 1 Pg. 173-5 (Nov 15 1998) ISSN: 0888-7543 [Print] United States
• PMID: 9806846 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
• Copyright: Copyright 1998 Academic Press.

Chemical References

• DNA, Complementary
• Nerve Tissue Proteins
• SNCA protein, human
• SNCB protein, human
• Synucleins
• alpha-Synuclein
• beta-Synuclein

Topics

• Amino Acid Sequence
• Base Sequence
• Brain (metabolism)
• DNA, Complementary
• Exons (genetics)
• Gene Expression
• Humans
• Introns (genetics)
• Molecular Sequence Data
• Nerve Tissue Proteins (chemistry, genetics)
• Polymerase Chain Reaction (methods)
• Synucleins
• alpha-Synuclein
• beta-Synuclein